Key Takeaways
- • Gujarat Themis Biosyn secured JPY21.5bn ($135 million) in financing to acquire Japanese drugmaker MicroBiopharm Japan, announced in May 2026 and now funded through a multi-source capital structure.
- • Asian private credit manager Orion Capital Asia provided JPY9.2bn ($58 million) in debt financing, representing a significant portion of the acquisition funding and reflecting growing institutional appetite for cross-border pharma M&A.
- • The company raised an additional INR5.85bn ($61 million) through private placement of rupee-denominated secured debt, with Indian managers Avendus Capital (lead investor) and Edelweiss Alternatives participating in the financing round.
- • Debt instruments include five-year debentures carrying a 10% coupon and 18-month notes paying 17.75%, with proceeds directed to Gujarat Themis' Japanese subsidiary for acquisition funding and general corporate purposes.
- • The transaction demonstrates the use of hybrid private credit structures to fund mid-market pharmaceutical M&A, combining foreign currency debt (Japanese yen) with domestic rupee placements to optimize cost of capital across jurisdictions.
Summary
Gujarat Themis Biosyn, an Indian pharmaceutical company, has completed its financing for the JPY21.5bn ($135 million) acquisition of MicroBiopharm Japan through a multi-tranche capital structure combining private credit and debt placements. The company announced the acquisition target in May 2026 and has now assembled the necessary funding through both foreign and domestic sources.
The deal structure reflects a hybrid approach to cross-border pharma acquisition financing. Orion Capital Asia, an Asian private credit manager, provided JPY9.2bn ($58 million) in financing—representing approximately 43% of the total acquisition value. This component underscores the increasing relevance of private credit markets in funding mid-market M&A activity in Asia, particularly for strategic acquisitions in the pharmaceutical sector where operational synergies and geographic expansion drive deal rationale.
Complementing the Orion facility, Gujarat Themis raised INR5.85bn ($61 million) through a private placement of secured debt instruments denominated in Indian rupees. Avendus Capital and Edelweiss Alternatives, both Indian-based alternative credit managers, participated as investors in this domestic financing round, with Avendus positioned as a lead investor. The rupee-denominated debt comprises two tranches: five-year debentures carrying a 10% coupon and 18-month notes yielding 17.75%, reflecting the higher return expectations typical of subordinated or secured debt instruments in Indian credit markets.
According to Gujarat Themis, the proceeds from both the private credit facility and the debt placement will be directed to its wholly owned Japanese subsidiary to fund the acquisition consideration, with surplus capital allocated for general corporate purposes. This structure—utilizing a Japanese subsidiary as the acquisition vehicle with funding sourced from both Asian private credit markets and domestic Indian debt markets—optimizes the company's capital efficiency while managing foreign exchange and currency exposure across jurisdictions.
The deal structure reflects a hybrid approach to cross-border pharma acquisition financing. Orion Capital Asia, an Asian private credit manager, provided JPY9.2bn ($58 million) in financing—representing approximately 43% of the total acquisition value. This component underscores the increasing relevance of private credit markets in funding mid-market M&A activity in Asia, particularly for strategic acquisitions in the pharmaceutical sector where operational synergies and geographic expansion drive deal rationale.
Complementing the Orion facility, Gujarat Themis raised INR5.85bn ($61 million) through a private placement of secured debt instruments denominated in Indian rupees. Avendus Capital and Edelweiss Alternatives, both Indian-based alternative credit managers, participated as investors in this domestic financing round, with Avendus positioned as a lead investor. The rupee-denominated debt comprises two tranches: five-year debentures carrying a 10% coupon and 18-month notes yielding 17.75%, reflecting the higher return expectations typical of subordinated or secured debt instruments in Indian credit markets.
According to Gujarat Themis, the proceeds from both the private credit facility and the debt placement will be directed to its wholly owned Japanese subsidiary to fund the acquisition consideration, with surplus capital allocated for general corporate purposes. This structure—utilizing a Japanese subsidiary as the acquisition vehicle with funding sourced from both Asian private credit markets and domestic Indian debt markets—optimizes the company's capital efficiency while managing foreign exchange and currency exposure across jurisdictions.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.